109451
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
2 型糖尿病合并下肢动脉疾病患者血清 CCL26 和 CCR3 的变化及诊断价值
Authors Zhang X , Jia T, Li L, Jiang X, Wang M
Received 15 May 2025
Accepted for publication 26 September 2025
Published 15 October 2025 Volume 2025:21 Pages 823—833
DOI https://doi.org/10.2147/VHRM.S540586
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Harry Struijker-Boudier
Xuyan Zhang,* Ting Jia,* Li Li, Xiaowan Jiang, Mengjie Wang
Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xuyan Zhang, Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Jiang’an District, Wuhan, Hubei, 430014, People’s Republic of China, Email Zhangxuuyan21@163.com
Objective: To investigate the serum levels of Chemokine CCL26 (CCL26) and Receptors, CCR3 (CCR3) in patients with Diabetes Mellitus, Type 2 (T2DM) complicated by lower extremity artery disease (LEAD), and to evaluate their potential as diagnostic biomarkers for T2DM with LEAD.
Methods: A retrospective study was conducted involving 197 patients with T2DM between June 2022 and February 2025. Patients were divided into T2DM group (n=157) and LEAD group (n=40). Clinical data and fasting venous blood were collected to measure serum CCL26 and CCR3 levels. Pearson correlation analysis was used to assess the correlation between CCL26 and CCR3. Lasso regression and logistic regression models were employed to identify risk factors for LEAD. The receiver operating characteristic (ROC) curve was constructed to evaluate the predictive efficacy of CCL26 and CCR3 for LEAD.
Results: The LEAD group had significantly higher BMI, disease duration, HbA1C, FINS, and HOMA-IR compared to the T2DM group (P< 0.05). Serum levels of CCL26 and CCR3 were elevated in the LEAD group (P< 0.05). A positive correlation was found between CCL26 and CCR3 (r=0.337, P=0.034). Lasso regression identified 12 indicators, including CCL26 and CCR3, as predictors of LEAD. Logistic regression revealed that BMI, disease duration, HbA1C, CCL26, and CCR3 were independent risk factors for LEAD (P< 0.05). The combined detection of serum CCL26 and CCR3 had an AUC of 0.812, indicating high predictive value for LEAD in T2DM patients.
Conclusion: Serum CCL26 and CCR3 levels are elevated in T2DM patients with LEAD and are closely associated with its occurrence. Combined detection of these biomarkers shows good predictive value for LEAD in T2DM patients.
Keywords: diabetes mellitus, type 2, peripheral arterial disease, chemokine CCL26, receptors, CCR3
Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Xuyan Zhang, Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, No. 26 Shengli Street, Jiang’an District, Wuhan, Hubei, 430014, People’s Republic of China, Email Zhangxuuyan21@163.com
Objective: To investigate the serum levels of Chemokine CCL26 (CCL26) and Receptors, CCR3 (CCR3) in patients with Diabetes Mellitus, Type 2 (T2DM) complicated by lower extremity artery disease (LEAD), and to evaluate their potential as diagnostic biomarkers for T2DM with LEAD.
Methods: A retrospective study was conducted involving 197 patients with T2DM between June 2022 and February 2025. Patients were divided into T2DM group (n=157) and LEAD group (n=40). Clinical data and fasting venous blood were collected to measure serum CCL26 and CCR3 levels. Pearson correlation analysis was used to assess the correlation between CCL26 and CCR3. Lasso regression and logistic regression models were employed to identify risk factors for LEAD. The receiver operating characteristic (ROC) curve was constructed to evaluate the predictive efficacy of CCL26 and CCR3 for LEAD.
Results: The LEAD group had significantly higher BMI, disease duration, HbA1C, FINS, and HOMA-IR compared to the T2DM group (P< 0.05). Serum levels of CCL26 and CCR3 were elevated in the LEAD group (P< 0.05). A positive correlation was found between CCL26 and CCR3 (r=0.337, P=0.034). Lasso regression identified 12 indicators, including CCL26 and CCR3, as predictors of LEAD. Logistic regression revealed that BMI, disease duration, HbA1C, CCL26, and CCR3 were independent risk factors for LEAD (P< 0.05). The combined detection of serum CCL26 and CCR3 had an AUC of 0.812, indicating high predictive value for LEAD in T2DM patients.
Conclusion: Serum CCL26 and CCR3 levels are elevated in T2DM patients with LEAD and are closely associated with its occurrence. Combined detection of these biomarkers shows good predictive value for LEAD in T2DM patients.
Keywords: diabetes mellitus, type 2, peripheral arterial disease, chemokine CCL26, receptors, CCR3